These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 21426837)
21. [Toxicity research status of benzalkonium chloride on ocular surface]. Huang C; Chen W; Chen Y; Liu Z Zhonghua Yan Ke Za Zhi; 2014 Apr; 50(4):303-6. PubMed ID: 24931157 [TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of topical travoprost with sofzia preservative for Japanese glaucoma patients. Kanamoto T; Kiuchi Y; Suehiro T; Nakano T; Nakano Y; Hirota A; Miyata A Hiroshima J Med Sci; 2010 Dec; 59(4):71-5. PubMed ID: 21361083 [TBL] [Abstract][Full Text] [Related]
23. [Treatment of glaucoma in patients with dry eye syndrome]. Labbé A; Baudouin C J Fr Ophtalmol; 2010 Apr; 33(4):285-90. PubMed ID: 20304521 [TBL] [Abstract][Full Text] [Related]
24. A rabbit dry eye model induced by topical medication of a preservative benzalkonium chloride. Xiong C; Chen D; Liu J; Liu B; Li N; Zhou Y; Liang X; Ma P; Ye C; Ge J; Wang Z Invest Ophthalmol Vis Sci; 2008 May; 49(5):1850-6. PubMed ID: 18436819 [TBL] [Abstract][Full Text] [Related]
25. [Effect of preservatives on the conjunctiva: a comparative study of beta-blocker eye drops with and without preservatives in glaucoma patients]. Pisella PJ; Lala E; Parier V; Brignole F; Baudouin C J Fr Ophtalmol; 2003 Sep; 26(7):675-9. PubMed ID: 13130254 [TBL] [Abstract][Full Text] [Related]
26. [Glaucoma and dry eye. Current concepts and future perspectives]. Steven P; Cursiefen C Ophthalmologe; 2013 Dec; 110(12):1155-9. PubMed ID: 24129917 [TBL] [Abstract][Full Text] [Related]
27. [The deleterious effect of certain surface active agents on the ocular surface]. Ravet O Bull Soc Belge Ophtalmol; 2007; (304):145-9. PubMed ID: 17718239 [TBL] [Abstract][Full Text] [Related]
28. Side effects of glaucoma medications. Detry-Morel M Bull Soc Belge Ophtalmol; 2006; (299):27-40. PubMed ID: 16681086 [TBL] [Abstract][Full Text] [Related]
30. [Effects of preservatives in anti-glaucoma agents on the ocular surface]. Potop V Oftalmologia; 2009; 53(2):92-6. PubMed ID: 19697847 [TBL] [Abstract][Full Text] [Related]
31. Efficacy of indomethacin 0.1% and fluorometholone 0.1% on conjunctival inflammation following chronic application of antiglaucomatous drugs. Baudouin C; Nordmann JP; Denis P; Creuzot-Garcher C; Allaire C; Trinquand C Graefes Arch Clin Exp Ophthalmol; 2002 Nov; 240(11):929-35. PubMed ID: 12486516 [TBL] [Abstract][Full Text] [Related]
32. [Flow cytometric analysis of HLA-DR, IL-6 and IL-8 expression by conjunctival epithelial cells from patients with prolonged topical antiglaucoma treatments]. Bensoussan L; Blondin C; Baudouin C; Hamard P; Sabeh Afaki G; Creuzot-Garcher C; Warnet JM; Brignole-Baudouin F J Fr Ophtalmol; 2003 Oct; 26(8):782-9. PubMed ID: 14586218 [TBL] [Abstract][Full Text] [Related]
33. Relationship between OSDI score and biomicroscopic ocular surface damages in glaucomatous patients treated with preserved antiglaucomatous eye drops. Lajmi H; Chelly Z; Choura R; Mansour KB; Hmaied W J Fr Ophtalmol; 2021 Nov; 44(9):1326-1331. PubMed ID: 34325926 [TBL] [Abstract][Full Text] [Related]